Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Venlafaxine
Drug ID BADD_D02346
Description Venlafaxine (Effexor) is an antidepressant within the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medications. It exerts its effects primarily by blocking the transporters involved in the reuptake of the neurotransmitters serotonin and norepinephrine, therefore leaving more active neurotransmitter in the synapse. Venlafaxine is officially approved for use in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. As of 2014, Canadian clinical practice guidelines recommend venlafaxine as a first-line option for treatment of generalized anxiety, social anxiety, panic disorder, major depressive disorder (MDD), and consider it a second-line option for management of obsessive-compulsive disorder (OCD) [A177226,A177235]. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232].
Indications and Usage For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.
Marketing Status Prescription; Discontinued
ATC Code N06AX16
DrugBank ID DB00285
KEGG ID D08670
MeSH ID D000069470
PubChem ID 5656
TTD Drug ID D0P1UX
NDC Product Code 71209-025; 46708-433; 43602-392; 23155-246; 68001-156; 46708-431; 50268-801; 43598-944; 70518-3269; 65162-305; 62332-010; 68084-856; 57664-396; 16714-655; 57664-394; 51407-454; 68001-497; 63187-414; 43602-393; 50090-4715; 72865-200; 67877-727; 50090-2210; 62332-008; 63187-929; 65162-302; 68382-021; 71335-0778; 23155-250; 72865-198; 72865-199; 61919-495; 0527-2606; 51407-457; 71610-606; 60760-713; 51407-455; 51407-456; 71209-088; 43598-943; 67877-729; 50268-800; 63187-752; 31722-123; 71335-0449; 46708-434; 68001-159; 51407-453; 43063-633; 16714-659; 50268-798; 68001-498; 23155-247; 65162-306; 61919-351; 57664-392; 68084-896; 57664-395; 68001-157; 50090-4805; 61919-938; 71209-027; 67877-726; 65162-307; 23155-249; 31722-125; 70518-1245; 16714-656; 71209-029; 71209-087; 62332-012; 57664-393; 68382-020; 68382-018; 43602-395; 68382-019; 46708-432; 50090-4865; 31722-126; 67877-728; 16714-658; 68001-496; 23155-248; 16714-657; 71209-089; 70518-1547; 70518-2751; 50268-799; 68001-160; 62332-011; 43602-394; 31722-124; 50090-2408; 68084-844; 71209-026; 62332-009; 65162-300; 72865-197; 68071-4341; 71209-028; 68382-101; 46708-430; 61919-535; 68001-158; 68001-499
Synonyms Venlafaxine Hydrochloride | Hydrochloride, Venlafaxine | Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride | 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl | Wy 45030 | Wy-45030 | Wy45030 | Wy-45,030 | Wy 45,030 | Wy45,030 | Sila-Venlafaxine | Sila Venlafaxine | Effexor | Trevilor | Vandral | Efexor | Venlafaxine | Dobupal
Chemical Information
Molecular Formula C17H27NO2
CAS Registry Number 93413-69-5
SMILES CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Metabolic disorderActivity-regulated cytoskeleton-associated proteinQ9WV31Not Available14580947; 15838995; 15087240
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Antipsychotic drug level increased13.17.01.0300.000149%Not Available
Atrioventricular septal defect03.07.02.005; 02.04.02.0290.000447%Not Available
Congenital heart valve disorder03.07.05.001; 02.07.02.0020.000149%Not Available
Atypical fibroxanthoma23.08.02.009; 16.03.02.0090.000224%Not Available
Tachyphrenia19.10.03.010; 17.03.03.0070.000298%Not Available
Burnout syndrome19.06.06.0030.000373%Not Available
Virologic failure11.01.08.062; 08.06.01.0340.000224%Not Available
VACTERL syndrome22.04.07.012; 15.03.01.026; 07.11.04.011; 03.02.01.013; 02.08.02.010; 24.03.02.0300.000117%Not Available
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.002980%Not Available
Tethered cord syndrome17.10.01.023; 20.03.03.0070.000136%Not Available
Basal ganglia haemorrhage24.07.04.021; 17.08.01.0390.000298%Not Available
Carotid arteriosclerosis24.04.06.031; 17.08.02.0150.000149%Not Available
Congenital naevus23.10.01.004; 16.26.01.004; 03.05.01.0020.000224%Not Available
Right aortic arch24.03.03.039; 03.07.08.0080.000039%Not Available
Apparent death08.01.03.0620.000149%Not Available
Quality of life decreased13.18.01.0130.000447%Not Available
Congenital tricuspid valve incompetence02.07.05.003; 03.07.05.0120.000149%Not Available
Foetal hypokinesia18.03.02.0150.000097%Not Available
Frontotemporal dementia19.20.02.008; 17.03.01.0070.000149%Not Available
Gross motor delay19.22.01.004; 17.01.02.0210.000224%Not Available
Coma scale abnormal13.07.03.0120.000373%Not Available
Herbal interaction08.06.03.0050.000298%Not Available
False positive investigation result13.18.01.0070.000149%Not Available
Encephalitis autoimmune17.06.05.002; 16.32.01.006; 10.04.10.0120.000149%Not Available
Neonatal behavioural syndrome22.11.02.007; 18.04.04.010; 17.02.05.058; 15.05.04.0200.000596%Not Available
Infantile haemangioma24.03.06.009; 16.02.01.0070.000224%Not Available
Urinary tract discomfort20.02.03.0170.000149%Not Available
Neuronal migration disorder17.19.03.008; 03.10.03.0090.000224%Not Available
Helplessness19.01.02.0130.000149%Not Available
Infantile apnoea22.11.02.004; 18.04.15.0030.000820%Not Available
The 39th Page    First    Pre   39 40    Next   Last    Total 40 Pages